Volume 59(5); May

< Previous     Next >

Article Contents

Clin Exp Pediatr > Volume 59(5); 2016
Kim, Cho, Baek, Li, Baek, Kim, Kim, and Sheen: Lipopolysaccharide-binding protein plasma levels as a biomarker of obesity-related insulin resistance in adolescents



Lipopolysaccharide-binding protein (LBP) is a 65-kDa acute phase protein, derived from the liver, which is present in high concentrations in plasma. Data regarding the association between circulating plasma LBP levels and obesity-related biomarkers in the pediatric population are scarce. We aimed to determine whether there was a difference in plasma LBP levels between overweight/obese and normal-weight adolescents and to assess the correlation of circulating LBP levels with anthropometric measures and obesity-related biomarkers, including insulin resistance, liver enzyme levels, and lipid profiles.


The study included 87 adolescents aged 12–13 years; 44 were overweight/obese and 43 were of normal-weight. We assessed anthropometric and laboratory measures, including body mass index (BMI), blood pressure, insulin resistance, liver enzyme levels, and lipid profiles. Plasma LBP levels were measured using an enzyme-linked immunosorbent assay.


The mean age of the participants was 12.9±0.3 years. Circulating plasma LBP levels were significantly increased in overweight/obese participants compared with those in normal-weight participants (7.8±1.9 µg/mL vs. 6.0±1.6 µg/mL, P<0.001). LBP levels were significantly and positively associated with BMI, systolic blood pressure, aspartate aminotransferase, alanine aminotransferase, total cholesterol, low density lipoprotein-cholesterol, fasting glucose and insulin, and insulin resistance as indicated by the homeostatic model assessment of insulin resistance (HOMA-IR) (all P<0.05). In multivariate linear regression analysis, BMI and HOMA-IR were independently and positively associated with plasma LBP levels.


LBP is an inflammatory biomarker associated with BMI and obesity-related insulin resistance in adolescents. The positive correlation between these parameters suggests a potentially relevant pathophysiological mechanism linking LBP to obesity-related insulin resistance in adolescents.


Obesity has become a significant public health concern and is now occurring at younger ages worldwide1). Mounting evidence suggests that childhood overweightness and obesity often continues into adulthood and is associated with increased morbidity and mortality in adulthood2). This metabolic disorder increases the risk of cardiovascular diseases, ultimately causing premature death3).
In recent years, it has become apparent that increases in a variety of inflammatory biomarkers are associated with obesity in children and their morbid consequences4). However, the mechanisms that trigger the increased inflammatory burden remain elusive. A previously unrecognized source of proinflammatory factors includes the complex ecology of mucosal surface microbes and, most importantly, the gut microbiome5). Changes in the gut microbiome stimulate microbial translocation, i.e., the transfer of microbial organisms or some of their products across intestinal mucosal barriers without definite low-grade bacteremia6). Obesity is one of various conditions related to increased microbial translocation, in particular of lipopolysaccharide (LPS)7,8,9).
One of the endogenous reactive biomarkers produced in response to microbial translocation is lipopolysaccharide-binding protein (LBP), a 65-kDa soluble acute phase protein that is mainly produced by hepatocytes10) but is also expressed and released by intestinal epithelial cells11) and visceral adipocytes12). Plasma LBP levels increase greatly in response to inflammatory challenges, including bacterial sepsis13) and a high-fat, high-carbohydrate meal14). Although the molecular basis of LBP formation is not fully established, LBP is known to bind to LPS (and LPS substructures, such as lipid IVa) via recognition of lipid A15). Plasma LBP dramatically accelerates the binding of LPS monomers released from aggregates to CD1416), thereby increasing the sensitivity of cells to LPS. Additionally, LBP functions as a lipid transfer protein, a function consistent with its sequence homology to lipid transferases (phospholipid transfer protein and cholesterol ester transfer protein)9). LBP copurifies with high-density lipoprotein (HDL) particles and previous studies have demonstrated that LBP can relocate LPS to lipoproteins, counteracting the LPS effects17).
Despite increasing evidence that LBP plays an important role in the pathophysiology of cardiovascular diseases18) and obesity9,19,20), no studies have investigated the relationship between circulating concentrations of LBP and obesity-related biomarkers in adolescent populations. Understanding these relationships in adolescent populations might help advance our understanding of the pathophysiology of adolescent obesity, which is generally known to persist into adulthood, and might lead to prevention, early diagnosis, and the development of novel treatments for obesity.
The aims of the present study were to determine whether there is a difference in plasma LBP levels between overweight/obese and normal-weight subjects and to assess the relationship between plasma LBP levels and anthropometric measures and obesity-related biomarkers, such as insulin resistance, liver enzymes, and lipid profiles, in a population of adolescents.

Materials and methods

1. Study subjects

One hundred two adolescents aged 12 to 13 years underwent Student Health Examinations at a designated health promotion center in Seoul, Korea from May through August 2015. Subjects meeting any of the following criteria were excluded (n=15): any missing covariate information; a medication history of steroids, insulin, glucose regulators, or antihypertensive drugs; refusal to take the test; or failure to fast for at least 12 hours before blood sampling. After these exclusions, 87 subjects (55 boys and 32 girls) were included in the final analysis. Health examinations were performed by a single physician according to a standardized procedure. Body weight and height were measured to the nearest 0.1 kg and 0.1 cm, respectively, using an automatic height–weight scale and with the subjects wearing light indoor clothing and no shoes. BMI was calculated as weight (kg)/height (m2). The BMI percentiles for age and sex were determined according to the 2007 Korea Growth Charts21). The subjects were subdivided into 2 groups according to their BMI value: a normal-weight subgroup (BMI<85th percentile) and an overweight/obese subgroup (BMI≥85th percentile). A registered nurse measured blood pressure (BP) a maximum of 3 times on the right arm in seated subjects after a 5-minute rest using a sphygmomanometer. The sexual maturity rating was assessed according to Tanner stages by the physician. The Institutional Review Board approved the study, and written informed consent was obtained from the subjects and their parents or guardians.

2. Laboratory analyses for obesity-related biomarkers

Following a 12-hour overnight fast, blood samples were obtained from the antecubital vein of each subject by venipuncture and were immediately centrifuged, aliquoted, and frozen at -20℃. The frozen serum and plasma samples were stored at -80℃ until analysis. Fasting serum glucose, total cholesterol, triglyceride, and HDL-cholesterol (HDL-C) levels were measured by enzymatic methods using a Hitachi Modular D2400 automated chemistry analyzer (Hitachi, Tokyo, Japan). Levels of low-density lipoprotein-cholesterol (LDL-C) were calculated using the following formula: LDL-C=total cholesterol-HDL-C-(triglyceride/5). Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were measured. Fasting insulin levels were measured using a chemiluminescent microparticle immunoassay (Abbott Architect system, Irving, TX, USA). Insulin resistance was estimated using the homeostatic model assessment of insulin resistance (HOMA-IR) and calculated using the following formula: HOMA-IR=[fasting insulin (µIU/mL)×fasting glucose (mg/dL)/18]/22.522).

3. Measurement of plasma LBP

Concentrations of plasma LBP were measured using commercially available enzyme-linked immunosorbent assay (ELISA) kits (Duoset, R&D Systems, Minneapolis, MN, USA) in duplicate according to the manufacturer's instruction. Plasma samples were diluted 1,000 folds. The minimum detectable concentration of LBP was 0.78 ng/mL. No cross-reactivity or interference was observed with LBP. The absorbance values for the ELISA were determined using an Infinite 2000 Pro Multimode Plate Reader (Tecan, Vienna, VA, USA) at an optical absorbance of 450 nm. The final concentration was determined with reference to a standard curve.

4. Statistical analysis

All continuous variables are presented as mean±standard deviation or are shown as scatter plots. Between-group differences were compared using independent Student t tests, Kruskal-Wallis tests, Mann-Whitney U tests, or chi-square tests, as appropriate. Pearson correlation analyses were used to calculate the correlation between plasma LBP levels and anthropometric measures and obesity-related biomarkers. Anthropometric and biochemical parameters according to LBP quartiles were summarized using the Kruskal-Wallis test for continuous variables and the chi-square test for categorical variables. LBP quartiles were categorized separately as follows: Q1, <5.4; Q2, 5.4–6.6; Q3, 6.7–8.2; and Q4, >8.2. To examine independent correlates of plasma LBP levels, a multivariate linear regression analysis was conducted with plasma LBP level as the dependent variable. All statistical analyses were performed using SAS ver. 9.2 (SAS Institute Inc., Cary, NC, USA). All statistical tests were two-sided, with a P value <0.05 indicating statistical significance.


1. Population characteristics

The mean age of the study subjects was 12.9±0.3 years. Forty-four subjects were overweight (25 subjects) or obese (19 subjects) and 43 subjects were of normal-weight. There were 55 boys (63.2 %) and 32 girls (36.8%) in the study population.

2. Comparison of clinical and laboratory parameters between overweight/obese and normal-weight subjects

Table 1 compares clinical and laboratory parameters for overweight/obese and normal-weight subjects. In the anthropometric measures, weight, weight z score, BMI, BMI z score, and systolic and diastolic BP were significantly higher in the overweight/obese subjects compared with normal-weight subjects (all P<0.05)(Table 1). There were no differences in sex, age, height, height z score, and Tanner stages between groups. For laboratory parameters, AST, ALT, total cholesterol, LDL-cholesterol, triglyceride, insulin, HOMA-IR, and LBP were significantly higher in the overweight/obese subjects compared with normal-weight subjects (all P<0.05) (Table 1). There were no between-group differences in HDL-cholesterol and fasting glucose levels (Table 1).

3. Associations of LBP with anthropometric measures and obesity-related biomarkers

Pearson correlation coefficients between plasma LBP levels and various parameters are listed in Table 2. Plasma LBP level was significantly and positively correlated with weight and weight z score (r=0.60, P<0.001), BMI (r=0.63, P<0.001; Fig. 1A) and BMI z score, systolic BP (r=0.23, P=0.04), AST (r=0.34, P=0.002), ALT (r=0.41, P<0.001; Fig. 1B), total cholesterol (r=0.23, P=0.04), LDL-cholesterol (r=0.26, P=0.02; Fig. 1C), fasting glucose (r=0.24, P=0.02), fasting insulin (r=0.60, P<0.001), and HOMA-IR (r=0.57, P<0.001; Fig. 1D). No significant correlations were observed between plasma LBP levels and age, height, height z score, diastolic BP, HDL-cholesterol, or triglyceride. BMI, BMI z score, systolic BP, AST/ALT, fasting glucose, fasting insulin, and HOMA-IR increased significantly according to LBP quartiles (all P<0.05)(Table 3). No differences in plasma LBP levels were observed according to Tanner stage. In a multivariate linear regression analysis, BMI and HOMA-IR were independently and positively associated with plasma LBP levels (Table 4).


The aims of the present study were to determine whether there were differences in plasma LBP levels between overweight/obese and normal-weight subjects and to assess the relationships of LBP with anthropometric measures and obesity-related biomarkers, including BMI, insulin resistance, liver enzymes, and lipid profiles, in young adolescents. We found significantly higher plasma LBP levels in overweight/obese adolescents compared with normal-weight adolescents and a significant positive association between plasma LBP levels and BMI and HOMA-IR in a multivariate linear regression analysis. To the best of our knowledge, this is the first report of a significant positive association between plasma LBP levels and BMI and HOMA-IR in an adolescent population.
The prevalence of obesity and metabolic syndrome is increasing across the globe1). Despite intensified research, the pathogenesis and pathophysiology of these complex diseases are not well understood. Recent studies have reported that obese adults have higher circulating plasma LBP concentrations than controls, suggesting that LBP may be a surrogate marker of underlying low-grade endotoxemia caused by LPS from the gut, which ultimately leads to the development of obesity and metabolic derangements7,9). In line with previous studies in adults, we found significantly higher plasma LBP levels in overweight/obese adolescents than in normal-weight adolescents. Furthermore, we showed a significant positive association of plasma LBP concentration with BMI and HOMA-IR, even after adjusting for potential confounders.
There may be congruent molecular mechanisms explaining why plasma LBP concentrations are closely associated with BMI and HOMA-IR. One possible explanation is that upstream changes in the gut microbiota in overweight/obese adolescents promote alterations in intestinal permeability or cause microbial translocation that would result in low levels of systemic LPS6). Once in the circulation, LPS forms a complex with LBP15) that would bind to CD1416), resulting in innate immunity events and development of a low-grade systemic inflammatory response with production of tumor necrosis factor (TNF)-α and interleukin (IL)-6. These proinflammatory cytokines block insulin action in adipocytes via autocrine/paracrine signaling and cause systemic insulin resistance via endocrine signaling23,24,25). The association of the gut microbiome with insulin resistance is supported by a recent study that assessed the effect of dietary intervention targeting the gut microbiota on chronic inflammation underlying metabolic syndrome in adults; the authors reported that modulation of the gut microbiota via dietary intervention improved the intestinal barrier integrity, changed the gut microbiome by decreasing endotoxin-producing opportunistic pathogens of Enterobacteriaceae and Desulfovibrionaceae and increasing gut barrier-protecting bacteria of Bifidobacteriaceae, decreased plasma levels of LBP, TNF-α, and IL-6, and ameliorated insulin resistance, eventually alleviating the inflammation and metabolic phenotypes26). Taken together, these observations suggest that measurement of plasma LBP levels might provide a potential biochemical indicator for adolescents at risk for metabolic abnormalities.
The finding of increased plasma LBP levels in overweight/obese adolescents was novel. There are a few studies in the literature reporting the association between LBP levels and obesity in younger children. A study by Luoto et al.8) followed 15 overweight and 15 normal-weight children from the age of 3 months through 10 years and found that the children who were normal weight at age 10 had higher serum concentrations of soluble CD14 that binds to LBP at age 3 months than those who were overweight at age 10, but LBP levels did not differ between groups; they did not look at the association of LBP with HOMA-IR. Another study of 219 children (mean age, 6.8±1.3 years) reported that LBP was independently and positively associated with BMI and with measures of obstructive sleep apnea severity, as well as with metabolic dysfunction, particularly insulin resistance as illustrated by the HOMA-IR27). This previous finding corresponds well with our results in that the increased plasma LBP levels in overweight/obese adolescents were closely related to increased metabolic abnormalities, particularly insulin resistance. The present study is unique in that we focused on young adolescents aged 12–13 years. Adolescence is a crucial period for establishing healthy lifestyle patterns and many of the habits formed during this developmental stage last well into adulthood28). Therefore, it is of critical importance that clinicians detect adolescents at risk of obesity and/or metabolic abnormalities at an early stage and modify their lifestyle, such as diet patterns. In this regard, previous findings and our results are well aligned with the theory that changes in diet patterns in obese subjects will lead to fundamental modifications in gut microbiota, which will subsequently prevent the occurrence of obesity and metabolic derangements26,29,30).
LBP is mainly produced by hepatocytes10). There is recent evidence that LBP levels significantly correlate with levels of proinflammatory cytokines (IL-6 and IL-8) and liver enzymes (ALT and γ–glutamyltransferase)7). Liver metabolism plays a critical role in the pathogenesis of metabolic syndrome31) and insulin resistance31). Furthermore, there is evidence that the levels of liver enzymes increase before nonalcoholic fatty liver disease (NAFLD) develops, suggesting that liver enzymes may be a marker of NAFLD31,32,33). In the present study, ALT showed a statistically significant correlation with plasma LBP levels in univariate analysis, although this association was not maintained in the multivariate linear regression analysis. This discrepancy may reflect the fact that ALT is highly correlated with BMI and HOMA-IR31), a term known as collinearity of independent variables. Collectively, we found that plasma LBP levels were significantly and positively correlated with liver enzyme levels, a marker of liver damage and indicator of liver involvement in systemic inflammatory disease. These observations correspond well with previous studies showing that increased levels of bacterial compounds such as LPS play an important role in the development of NAFLD in obese individuals34,35).
The present study has limitations. The epidemiological cross-sectional design of this study does not allow for causal inference and does not give mechanistic insight into the association between plasma LBP levels and BMI and HOMA-IR.
In conclusion, we demonstrated higher plasma LBP levels in the presence of overweight/obesity in adolescents. Moreover, high plasma LBP levels are strongly associated with BMI and measures of insulin resistance. Advanced understanding of the causal relationships underlying these associations may not only lead to novel ways to identify adolescents at risk for such morbidities at an early stage, but also enable researchers to lay out therapeutic interventions, such as microbiome modifications through diet pattern changes or probiotics intake, with the intention of decreasing the degree and risk of some of the morbid consequences of adolescent obesity.


This study was supported by a 2014 research grant from the Korean Pediatric Society (Seokchun Award).

Conflicts of interest

Conflicts of interest:
No potential conflict of interest relevant to this article was reported.


1. Huffman MD, Capewell S, Ning H, Shay CM, Ford ES, Lloyd-Jones DM. Cardiovascular health behavior and health factor changes (1988-2008) and projections to 2020: results from the National Health and Nutrition Examination Surveys. Circulation 2012;125:2595–2602.
crossref pmid pmc
2. Reilly JJ, Kelly J. Long-term impact of overweight and obesity in childhood and adolescence on morbidity and premature mortality in adulthood: systematic review. Int J Obes (Lond) 2011;35:891–898.
crossref pmid
3. Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-Barbash R, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 2006;355:763–778.
crossref pmid
4. de Heredia FP, Gomez-Martinez S, Marcos A. Obesity, inflammation and the immune system. Proc Nutr Soc 2012;71:332–338.
crossref pmid
5. Tremaroli V, Backhed F. Functional interactions between the gut microbiota and host metabolism. Nature 2012;489:242–249.
crossref pmid
6. Shen J, Obin MS, Zhao L. The gut microbiota, obesity and insulin resistance. Mol Aspects Med 2013;34:39–58.
crossref pmid
7. Gonzalez-Quintela A, Alonso M, Campos J, Vizcaino L, Loidi L, Gude F. Determinants of serum concentrations of lipopolysaccharide-binding protein (LBP) in the adult population: the role of obesity. PLoS One 2013;8:e54600
crossref pmid pmc
8. Luoto R, Kalliomäki M, Laitinen K, Delzenne NM, Cani PD, Salminen S, et al. Initial dietary and microbiological environments deviate in normal-weight compared to overweight children at 10 years of age. J Pediatr Gastroenterol Nutr 2011;52:90–95.
crossref pmid
9. Moreno-Navarrete JM, Ortega F, Serino M, Luche E, Waget A, Pardo G, et al. Circulating lipopolysaccharide-binding protein (LBP) as a marker of obesity-related insulin resistance. Int J Obes (Lond) 2012;36:1442–1449.
crossref pmid
10. Wan Y, Freeswick PD, Khemlani LS, Kispert PH, Wang SC, Su GL, et al. Role of lipopolysaccharide (LPS), interleukin-1, interleukin-6, tumor necrosis factor, and dexamethasone in regulation of LPS-binding protein expression in normal hepatocytes and hepatocytes from LPS-treated rats. Infect Immun 1995;63:2435–2442.
crossref pmid pmc
11. Su GL, Freeswick PD, Geller DA, Wang Q, Shapiro RA, Wan YH, et al. Molecular cloning, characterization, and tissue distribution of rat lipopolysaccharide binding protein. Evidence for extrahepatic expression. J Immunol 1994;153:743–752.
crossref pmid pdf
12. Moreno-Navarrete JM, Escote X, Ortega F, Serino M, Campbell M, Michalski MC, et al. A role for adipocyte-derived lipopolysaccharide-binding protein in inflammation- and obesity-associated adipose tissue dysfunction. Diabetologia 2013;56:2524–2537.
crossref pmid
13. Grube BJ, Cochane CG, Ye RD, Green CE, McPhail ME, Ulevitch RJ, et al. Lipopolysaccharide binding protein expression in primary human hepatocytes and HepG2 hepatoma cells. J Biol Chem 1994;269:8477–8482.
crossref pmid
14. Ghanim H, Abuaysheh S, Sia CL, Korzeniewski K, Chaudhuri A, Fernandez-Real JM, et al. Increase in plasma endotoxin concentrations and the expression of Toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal: implications for insulin resistance. Diabetes Care 2009;32:2281–2287.
crossref pmid pmc
15. Tobias PS, Soldau K, Ulevitch RJ. Identification of a lipid A binding site in the acute phase reactant lipopolysaccharide binding protein. J Biol Chem 1989;264:10867–10871.
crossref pmid
16. Hailman E, Lichenstein HS, Wurfel MM, Miller DS, Johnson DA, Kelley M, et al. Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. J Exp Med 1994;179:269–277.
crossref pmid pmc
17. Wurfel MM, Kunitake ST, Lichenstein H, Kane JP, Wright SD. Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Med 1994;180:1025–1035.
crossref pmid pmc
18. Lepper PM, Kleber ME, Grammer TB, Hoffmann K, Dietz S, Winkelmann BR, et al. Lipopolysaccharide-binding protein (LBP) is associated with total and cardiovascular mortality in individuals with or without stable coronary artery disease----results from the Ludwigshafen Risk and Cardiovascular Health Study (LURIC). Atherosclerosis 2011;219:291–297.
crossref pmid
19. Liu X, Lu L, Yao P, Ma Y, Wang F, Jin Q, et al. Lipopolysaccharide binding protein, obesity status and incidence of metabolic syndrome: a prospective study among middle-aged and older Chinese. Diabetologia 2014;57:1834–1841.
crossref pmid
20. Sun L, Yu Z, Ye X, Zou S, Li H, Yu D, et al. A marker of endotoxemia is associated with obesity and related metabolic disorders in apparently healthy Chinese. Diabetes Care 2010;33:1925–1932.
crossref pmid pmc
21. Moon JS, Lee SY, Nam CM, Choi JM, Choe BK, Seo JW, et al. 2007 Korean National Growth Charts: review of developmental process and an outlook. Korean J Pediatr 2008;51:1–25.
22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–419.
crossref pmid
23. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006;116:1793–1801.
crossref pmid pmc
24. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993;259:87–91.
crossref pmid
25. Neels JG, Olefsky JM. Inflamed fat: what starts the fire? J Clin Invest 2006;116:33–35.
crossref pmid pmc
26. Xiao S, Zhao L. Gut microbiota-based translational biomarkers to prevent metabolic syndrome via nutritional modulation. FEMS Microbiol Ecol 2014;87:303–314.
crossref pmid
27. Kheirandish-Gozal L, Peris E, Wang Y, Tamae Kakazu M, Khalyfa A, Carreras A, et al. Lipopolysaccharide-binding protein plasma levels in children: effects of obstructive sleep apnea and obesity. J Clin Endocrinol Metab 2014;99:656–663.
crossref pmid
28. Challenges in Adolescent Health Care: Workshop Report. 2007. Committee on Adolescent Health Care Services and Models of Care for Treatment, Prevention, and Healthy Development; Board on Children, Youth, and Families; Division of Behavioral and Social Sciences and Education. Washington, D.C.: The National Academies Press, 2009.

29. Cani PD, Osto M, Geurts L, Everard A. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes 2012;3:279–288.
crossref pmid pmc
30. Tilg H, Kaser A. Gut microbiome, obesity, and metabolic dysfunction. J Clin Invest 2011;121:2126–2132.
crossref pmid pmc
31. Sookoian S, Pirola CJ. Alanine and aspartate aminotransferase and glutamine-cycling pathway: their roles in pathogenesis of metabolic syndrome. World J Gastroenterol 2012;18:3775–3781.
crossref pmid pmc
32. Adams LA, Feldstein AE. Nonalcoholic steatohepatitis: risk factors and diagnosis. Expert Rev Gastroenterol Hepatol 2010;4:623–635.
crossref pmid
33. Calcaterra V, Muratori T, Klersy C, Albertini R, Caramagna C, Brizzi V, et al. Early-onset metabolic syndrome in prepubertal obese children and the possible role of alanine aminotransferase as marker of metabolic syndrome. Ann Nutr Metab 2011;58:307–314.
crossref pmid
34. Ruiz AG, Casafont F, Crespo J, Cayón A, Mayorga M, Estebanez A, et al. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes Surg 2007;17:1374–1380.
crossref pmid
35. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001;48:206–211.
crossref pmid pmc
Fig. 1

Relationships between plasma LBP and BMI, ALT, LDL-cholesterol, and HOMA-IR in adolescents with and without overweight/obesity. (A) LBP vs. body mass index; (B) LBP vs. alanine aminotransferase; (C) LBP vs. LDL-cholesterol; and (D) LBP vs. homeostatic model assessment of insulin resistance. LBP, lipopolysaccharide-binding protein; BMI, body mass index; ALT, alanine aminotransferase; LDL-cholesterol, low density lipoprotein-cholesterol; HOMA-IR, homeostatic model assessment of insulin resistance.

Table 1

General characteristics of the study subjects

Characteristic Overweight/obese subjects (n=44) Normal-weight subjects (n=43) P value
Sex, boy:girl 30:14 25:18 0.33
Age (yr) 12.8±0.3 12.9±0.3 0.16
Height (cm) 160.6±6.6 159.5±7.4 0.49
Height z score 0.07±0.94 –0.08±1.06 0.49
Weight (kg) 67.7±8.7 49.2±8.0 <0.001
Weight z score 0.73±0.71 –0.75±0.64 <0.001
BMI (kg/m2) 26.2±2.3 19.3±2.5 <0.001
BMI z score 0.81±0.54 –0.83±0.60 <0.001
Tanner stage, n (%) 0.40
 I 4 (9.1) 2 (4.7)
 II 13 (29.5) 6 (14.0)
 III 21 (47.7) 29 (67.4)
 IV 6 (13.6) 6 (14.0)
Systolic BP (mmHg) 112.8±13.2 103.0±9.1 <0.001
Diastolic BP (mmHg) 64.5±10.9 60.4±7.5 0.045
Aspartate aminotransferase (IU/L) 24.3±15.7 18.4±4.2 0.02
Alanine aminotransferase (IU/L) 27.0±27.6 13.0±11.9 0.003
Total cholesterol (mg/dL) 167.0±31.1 153.0±27.8 0.03
HDL-cholesterol (mg/dL) 55.6±11.8 58.2±12.8 0.33
LDL-cholesterol (mg/dL) 90.7±25.7 80.3±22.4 0.047
Triglyceride (mg/dL) 101.1±59.2 70.1±32.5 0.003
Fasting glucose (mg/dL) 91.0±7.4 91.7±9.7 0.71
Fasting insulin (µIU/mL) 14.8±5.5 9.3±4.3 <0.001
HOMA-IR 3.4±1.5 2.2±1.2 <0.001
LBP (µg/mL) 7.8±1.9 6.0±1.6 <0.001

Values are presented as mean±standard deviation or number (%).

BMI, body mass index; BP, blood pressure; HDL-cholesterol, high density lipoprotein-cholesterol; LDL-cholesterol, low density lipoprotein-cholesterol; HOMA-IR, homeostatic model assessment of insulin resistance; LBP, lipopolysaccharide-binding protein.

Table 2

Correlations of plasma lipopolysaccharide-binding protein levels with various parameters

Variable Lipopolysaccharide-binding protein
R P value
Age (yr) –0.006 0.96
Height (cm) 0.09 0.39
Height z score 0.09 0.39
Weight (kg) 0.60 <0.001
Weight z score 0.60 <0.001
BMI (kg/m2) 0.63 <0.001
BMI z score 0.63 <0.001
Systolic BP (mmHg) 0.23 0.04
Diastolic BP (mmHg) 0.08 0.48
Aspartate aminotransferase (IU/L) 0.34 0.002
Alanine aminotransferase (IU/L) 0.41 <0.001
Total cholesterol (mg/dL) 0.23 0.04
HDL-cholesterol (mg/dL) –0.14 0.22
LDL-cholesterol (mg/dL) 0.26 0.02
Triglyceride (mg/dL) 0.20 0.06
Fasting glucose (mg/dL) 0.24 0.02
Fasting insulin (µIU/mL) 0.60 <0.001
HOMA-IR 0.57 <0.001

BMI, body mass index; BP, blood pressure; HDL-cholesterol, high density lipoprotein-cholesterol; LDL-cholesterol, low density lipoprotein-cholesterol; HOMA-IR, homeostatic model assessment of insulin resistance.

Table 3

Anthropometric and biochemical parameters according to plasma lipopolysaccharide-binding protein levels in the study subjects

Variable Q1 (<5.4) (n=23) Q2 (5.4-6.6) (n=21) Q3 (6.7-8.2) (n=21) Q4 (>8.2) (n=22) P value
Sex, boys:girls 12:11 10:11 13:8 20:2 0.01
Age (year) 12.8±0.3 13.0±0.3 12.9±0.3 12.9± 0.3 0.18
Height (cm) 158.6±7.9 160.5±7.4 161.1±6.3 160.3±6.4 0.67
Height z score –0.22±1.12 0.06±1.06 0.14±0.91 0.03±0.92 0.67
Weight (kg) 51.0±10.5 54.2±11.3 60.7±10.6 68.6±10.0 <0.001
Weight z score –0.61±0.84 –0.35±0.91 0.17±0.85 0.81±0.80 <0.001
BMI (kg/m2) 20.2±3.7 21.1±3.6 23.4±3.6 26.5±3.1 <0.001
BMI z score –0.61±0.88 –0.40±0.86 0.14±0.84 0.88±0.73 <0.001
Tanner stage, n (%) 0.48
 I 0 (0) 2 (9.5) 2 (9.5) 3 (13.6)
 II 3 (13.0) 2 (9.5) 4 (19.1) 9 (40.9)
 III 15 (65.2) 14 (66.7) 12 (57.1) 9 (40.9)
 IV 5 (21.7) 3 (14.3) 3 (14.3) 1 (4.6)
Systolic BP (mmHg) 101.7±9.9 111.1±12.3 108.7±10.4 110.7±14.3 0.03
Diastolic BP (mmHg) 58.4±8.5 64.2±11.4 64.0±9.4 63.4±8.2 0.13
AST (IU/L) 19.7±7.0 17.6±3.6 18.8±3.3 29.2±20.3 0.003
ALT (IU/L) 14.4±14.1 12.3±5.5 14.4±5.7 38.8±35.8 <0.001
Total cholesterol (mg/dL) 153.7±28.2 152.5±26.1 164.8±33.8 169.5±30.8 0.17
HDL-cholesterol (mg/dL) 61.3±13.1 55.8±12.7 54.0±12.2 56.2±10.7 0.23
LDL-cholesterol (mg/dL) 76.9±22.6 81.5±23.3 90.2±26.0 94.1±24.2 0.08
Triglyceride (mg/dL) 75.4±40.7 73.4±34.9 100.8±56.6 94.1±61.3 0.19
Fasting glucose (mg/dL) 88.7±5.9 90.6±7.0 90.1±7.8 96.0±11.3 0.02
Fasting insulin (µIU/mL) 9.4±5.2 10.4±3.6 11.2±4.0 17.3±6.0 <0.001
HOMA-IR 2.1±1.2 2.3±0.8 2.5±0.9 4.2±1.8 <0.001

Values are presented as mean±standard deviation or number (%).

P values were obtained using the Kruskal-Wallis test or the chi-square test.

BMI, body mass index; BP, blood pressure; AST, aspartate aminotransferase; ALT, alanine aminotransferase; HDL-cholesterol, high density lipoprotein-cholesterol; LDL-cholesterol, low density lipoprotein-cholesterol; HOMA-IR, homeostatic model assessment of insulin resistance.

Table 4

Assessment of the independent relationships between plasma lipopolysaccharide-binding protein levels and clinical variables

Variable Parameter, β SE P value
Body mass index (kg/m2) 0.221 0.049 <0.001
Systolic blood pressure (mmHg) –0.016 0.015 0.30
Alanine aminotransferase (IU/L) 0.006 0.009 0.54
LDL-cholesterol (mg/dL) 0.006 0.007 0.39
HOMA-IR 0.383 0.147 0.01

Multivariate linear regression analysis variables included body mass index, systolic blood pressure, alanine aminotransferase level, LDL-cholesterol level, and HOMA-IR as independent variables.

SE, standard error; LDL-cholesterol, low density lipoprotein-cholesterol; HOMA-IR, homeostatic model assessment of insulin resistance.

Close layer
prev next